Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

The apolipoprotein C-I content of very-low-density lipoproteins is associated with fasting triglycerides, postprandial lipemia, and carotid atherosclerosis.

Hansen JB, Fernández JA, Notø AT, Deguchi H, Björkegren J, Mathiesen EB.

J Lipids. 2011;2011:271062. doi: 10.1155/2011/271062. Epub 2011 Jul 6.

2.

The ApoC-I content of VLDL particles is associated with plaque size in persons with carotid atherosclerosis.

Notø AT, Mathiesen EB, Brox J, Björkegren J, Hansen JB.

Lipids. 2008 Jul;43(7):673-9. doi: 10.1007/s11745-008-3193-2. Epub 2008 May 29.

PMID:
18509687
4.

Postprandial enrichment of remnant lipoproteins with apoC-I in healthy normolipidemic men with early asymptomatic atherosclerosis.

Björkegren J, Silveira A, Boquist S, Tang R, Karpe F, Bond MG, de Faire U, Hamsten A.

Arterioscler Thromb Vasc Biol. 2002 Sep 1;22(9):1470-4.

PMID:
12231568
5.

Alimentary lipemia, postprandial triglyceride-rich lipoproteins, and common carotid intima-media thickness in healthy, middle-aged men.

Boquist S, Ruotolo G, Tang R, Björkegren J, Bond MG, de Faire U, Karpe F, Hamsten A.

Circulation. 1999 Aug 17;100(7):723-8.

PMID:
10449694
6.

Further characterization of the metabolic properties of triglyceride-rich lipoproteins from human and mouse apoC-III transgenic mice.

Aalto-Setälä K, Weinstock PH, Bisgaier CL, Wu L, Smith JD, Breslow JL.

J Lipid Res. 1996 Aug;37(8):1802-11.

7.

Postprandial remnant-like lipoproteins in hypertriglyceridemia.

Ooi TC, Cousins M, Ooi DS, Steiner G, Uffelman KD, Nakajima K, Simo IE.

J Clin Endocrinol Metab. 2001 Jul;86(7):3134-42.

PMID:
11443178
8.

Apolipoprotein C-III displacement of apolipoprotein E from VLDL: effect of particle size.

Breyer ED, Le NA, Li X, Martinson D, Brown WV.

J Lipid Res. 1999 Oct;40(10):1875-82.

9.
10.

The apolipoprotein CI content of triglyceride-rich lipoproteins independently predicts early atherosclerosis in healthy middle-aged men.

Hamsten A, Silveira A, Boquist S, Tang R, Bond MG, de Faire U, Björkegren J.

J Am Coll Cardiol. 2005 Apr 5;45(7):1013-7.

11.

Alterations of VLDL composition during alimentary lipemia.

Björkegren J, Hamsten A, Milne RW, Karpe F.

J Lipid Res. 1997 Feb;38(2):301-14.

13.
14.
15.

Apolipoprotein C-III and the metabolic basis for hypertriglyceridemia and the dense low-density lipoprotein phenotype.

Zheng C, Khoo C, Furtado J, Sacks FM.

Circulation. 2010 Apr 20;121(15):1722-34. doi: 10.1161/CIRCULATIONAHA.109.875807. Epub 2010 Apr 5.

16.

White adipose tissue apolipoprotein C-I secretion in relation to delayed plasma clearance of dietary fat in humans.

Wassef H, Salem H, Bissonnette S, Baass A, Dufour R, Davignon J, Faraj M.

Arterioscler Thromb Vasc Biol. 2012 Nov;32(11):2785-93. doi: 10.1161/ATVBAHA.112.300306. Epub 2012 Sep 20.

PMID:
22995522
17.

Abnormal lipid and apolipoprotein composition of major lipoprotein density classes in patients with chronic renal failure.

Attman PO, Alaupovic P, Tavella M, Knight-Gibson C.

Nephrol Dial Transplant. 1996 Jan;11(1):63-9.

PMID:
8649654
18.

Alterations in levels and interrelations of plasma apolipoproteins induced by diet.

Schonfeld G, Weidman SW, Witztum JL, Bowen RM.

Metabolism. 1976 Mar;25(3):261-75.

PMID:
175240
19.

Inhibitory effects of specific apolipoprotein C-III isoforms on the binding of triglyceride-rich lipoproteins to the lipolysis-stimulated receptor.

Mann CJ, Troussard AA, Yen FT, Hannouche N, Najib J, Fruchart JC, Lotteau V, André P, Bihain BE.

J Biol Chem. 1997 Dec 12;272(50):31348-54.

20.

Supplemental Content

Support Center